In a recent study, researchers compared the efficacy of several epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of certain types of non-small cell lung cancer. READ MORE
In a recent study, researchers compared the efficacy of several epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of certain types of non-small cell lung cancer.
A recent study showed that after performing next-generation sequencing of non-small cell lung cancer gene panels, actionable mutations were identifiable in 65% of cases with available targeted therapeutic options.
The US Food and Drug Administration has approved the supplemental New Drug Application for alectinib as a first-line treatment for patients with a specific type of lung cancer.
Ethnicity, insurance status, and other factors are associated with overall survival in patients with non-small cell lung cancer.
Research in Review
A new prognostic model provides personalized and disease-specific predictive information for patients with non-small cell lung cancer (NSCLC) and may result in better survival outcomes.
A second-generation inhibitor delays anaplastic lymphoma kinase-positive lung cancer growth for a median of 15 months longer and causes fewer adverse events than the current standard of care.
Few patients treated with immunotherapy for metastatic non–small cell lung cancer at US community practices receive appropriate programmed death-ligand 1 expression testing.
Patients with non-small cell lung cancer and synchronous brain metastasis demonstrate improved 1-year and 5-year overall survival after thoracic surgery and systemic chemotherapy.
Investigators assessed how response rate changed when patients were treated with different doses of brigatinib.
Investigators compared the safety and efficacy of docetaxel plus plinabulin with docetaxel alone in patients with NSCLC.
Using four key quality interventions in patients with non-small cell lung cancer who undergo surgery.
How does stereotactic body radiation therapy affected rates of non-cancer-related deaths?